strides good and approval, and our following therapy XX first gene Andrew, in building everyone. morning, Nearly months our incredible strengthening infrastructure. FDA Thanks, made have we commercial
to original hard an We XX see between our over unparalleled centers, beyond goal beginning are results experience of and XX of won qualified network far QTCs. XX with the treatment of this
access clear and demand our patient all established of have for We on paths both with to ZYNTEGLO and LYFGENIA. the for acceleration strong and therapies horizon starts in rapid
We encouraged extremely patients providers. the are by from excitement and
therapy there QTCs, on We years our continue that and to surpassed there X,XXX at hear we KOL the to recently serve. of experience. aim among And even gene more than communities recent through consistently at and which is belief patient calls conversations direct patient for data, in enthusiasm conferences confidence immense is
starts more than cell added ZYNTEGLO, including being approval in Today, launch both. with for for and collections year additional every already week. cell of for we thalassemia X in so have XX sickle announced LYFGENIA or XX XX completed have combined completed portfolio another XXXX far patient alone beta our across and Looked SKYSONA. the U.S. at across patient we been end starts X way, continues in XX XX with disease collection a the across starts of and cell of to portfolio total for And through our patient patients more scheduled our momentum commercial since the build XXXX
cell Importantly, disease. patients individuals with approximately of these sickle half living are
initiate therapies. room network, the have additional QTC than especially and XX tremendous patients process. of across begin to encouraged broad date, for treatment because have clearly treatment initiated are patients our We unique To we as the network for or centers our growth have that access XX-plus more QTCs, scheduled in our extensive to
for facility, growth and ZYNTEGLO which following and we at half the manufacturing recent be the of continues in demand to expansion Lonza very capacity year the ZYNTEGLO, strong, SKYSONA. anticipate our For continued doubles second our
starts of reinforces ability to acceleration portfolio year. us gives approximately in half the confidence XX and the second our this complete in year our we All across the projected of this
Additionally, first infusion is this recognizing exciting case, the being we've incredibly This the an and we recently revenue completed manufacturing now LYFGENIA time, is the fourth quarter. and this LYFGENIA first testing patient release milestone. In scheduled. or testing first manufacturing and on we third and for completed our release anticipate commercial in
Now moving to access and reimbursement.
always Our to access timely been equitable goal our therapies. has
to multiple includes means trial clinical at policies already prior Louisiana state We Pennsylvania live patients LYFGENIA. to patient both that are approval for states, that cell have patients including and criteria, cell for a just live This encouraged that aligned has state months, coverage has completed that process. for Medicaid commercial a X California, patient. with government LYFGENIA insured are the approving are which the least speed and with This of patients sickle affirmed disease. authorization access, is of than in by by through extremely LYFGENIA moving In many payers X in that sickle particularly more to half pathways coverage XX% published Medicaid
eager treatment list unlocking preferred to country. one Florida of I and highlight currently in largest sickle the in of in access in was June, of Medicaid LYFGENIA treatment. for specifically state want We Florida, critical populations for that patients a cell state drug the X placed centers the in are have a step the qualified to
outcomes-based multiple for lives. U.S. payers commercial place have national published in and XXX we in the LYFGENIA payer agreements commercial million more for place side, coverage than with On policies
therapy has access and either payers. Medicaid X continued with timely for and to ZYNTEGLO denials Additionally, ultimate commercial across both SKYSONA
approximately in LYFGENIA Moving the QTC to QTCs activated over field. the and network. our others has ZYNTEGLO size bluebird Today, in for of U.S., Xx the total XX
are our patients with network SKYSONA the X Additionally, activated for CALD. centers also to in of administer
for treatment a mentioned XX benefit network. with than experience are therapy gene showcasing I vast scheduled earlier, more our As of patients at bluebird the QTCs,
majority across efficacy, range mechanism found are action, key LYFGENIA see LYFGENIA. that that wide network, and continue preferred the time, QX measures, for cell recently and our QTC driving market manufacturing, including Most that research competitor in of We we to our of preference flexibility in key turnaround differentiators over collection conducted across we manufacturer a support.
through initial year capacity. our with launch and the ZYNTEGLO the expanded acceleration the anticipate expectations we outperforming newly our of recap, is remainder To
projected, SKYSONA expanding And and launch at starts patient this LYFGENIA accelerating continues begin planned journey. clip to year. launch the access a the to rapid treatment patients many As XX to the with is X scheduled progress with as expected
on XX towards patient approximately starts more look year, we patient starts for we As XX across track have the our the half scheduled, we back of already are and portfolio. than
I like to would over James. to now And the turn call
